Dr. Jorge Cortes discusses new data on bosutinib, a new tyrosine kinase inhibitor for CML.
Tuspetinib Exhibits Enhanced Efficacy in Diverse Newly Diagnosed AML Group
No minimal residual disease-negativity was observed with tuspetinib in patients with AML, including in a patient with more than 7 months of follow-up data.
Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy
Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.
Durable Response to CAR T is Associated With Elevated Activation and Clonotypic Expansion of the Cytotoxic Native T Cell Repertoire
Researchers have identified the transcription factor CEBPA as a crucial regulator of immune recognition in acute myeloid leukemia.
Immunotherapy Approaches in AML
Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.
sNDA Submitted to FDA for Venetoclax Plus Acalabrutinib in Untreated CLL
AMPLIFY trial results form the basis of the submission, with venetoclax/acalabrutinib showing a PFS advantage vs chemoimmunotherapy in patients with CLL.
Generic Ibrutinib Tablets Earn Tentative FDA Approval in Blood Cancers
Ibrutinib tablets will become available at 140 mg, 280 mg, and 420 mg for patients with chronic lymphocytic leukemia and Waldenström macroglobulinemia.
![We have the current CAR [T-cell therapies], which target CD19; however, we need others.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F6d5ddb2c2098f525a65b378ece6ca55a114f95fc-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "We have the current CAR [T-cell therapies], which target CD19; however, we need others.")
